You are here
The Future of MKIs / Questions & Answers
M. Peck-Radosavljevic MD (Austria) / All Faculty
Chair: M. Peck-Radosavljevic, MD
Faculty: Marcia Simpson Brose, MD; PhD, Bruno Daniele, MD, PhD; Rodolfo Sacco, MD, PhD
Markus Peck-Radosavljevic: Rodolfo, thank you very much, also for making up some time for us. My task is to give you a brief summary, and I will give you a very brief summary so that we have more time for discussions.
Basically the future is still there and very interesting for multikinase inhibitors, even these days when everybody is talking about immunotherapy, which obviously is something that will be interesting, but even when you look in one of the latest issues of Cell in one of the papers written by James Allison, he makes a strong argument for combining multikinase inhibitor therapy with immunotherapy so even if that is something that will be big in the future I think multikinase inhibitors are here to stay.